Jakavi 25mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.
Jakavi 25mg is a targeted therapy. It is an oral receptor tyrosine kinase inhibitor.
Jakavi 25mg works by blocking certain enzymes in the body that affect blood cell production.
Jakavi 25mg is prescription drug provided under supervision.
Ruxolitinib belongs to kinase inhibitor which is selective for the Janus analogue Kinases (JAK) 1 and 2. These kinases are necessary for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process contains signal transducers and transcription activators (STAT) which modulate gene expression. Patients having myelofibrosis contain abnormal JAK1 and JAK2 activity,henceRuxolitinibfunction to regulate this.
DOSAGE AND ADMINISTRATION
Kinase inhibitor uses for treatment of patients with intermediate or high-risk myelofibrosis, involving mainly myelofibrosis, post-polycythemiavera myelofibrosis and post-essential thrombocythemia myelofibrosis
Starting recommended doses for myelofibrosis :
If Platelet count >200 x10^9/L the dose given is 20 mg PO BID
If Platelet count 100-200 x10^9/L the dose given is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the dose given is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
Polycythemia Vera :
The recommended dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
Common side effects :
Serious side effects :
• Increased liver enzymes
• Increased cholesterol
• Shortness of breath
• Nausea & Vomiting
Treatment with Jakavi 10mg can resulted in thrombocytopenia, anemia and neutropenia. Control thrombocytopenia by decreasing the dose or temporarily interfere with Jakavi 25mg. Platelet transfusions may be necessary.
Risk of infection occurs by delay initiate treatment with Jakavi 25mg until active severe infection have resolved.
Tuberculosis infection has been reported in patients receiving Jakavi 25mg. Observe patients receiving Jakavi 25mg for signs and symptoms of active tuberculosis and manage promptly.
Progressive multifocal leukoencephalopathy (PML) has occurred with Jakavi 5mgtreatment. If PML is suspected, stop Jakavi 25mg and evaluate
Non-melanoma skin cancers including basal cell, squamous cell, and Merkel cell carcinoma have occurred in patients treated with Jakavi 25mg. Perform periodic skin examinations.